An interventional study of Nuan-gong-ye and Placebo in Chinese Medicine and Primary Dysmenorrhea, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-10.
Sponsored by China Medical University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Dysmenorrhea with a site in Taiwan — 4 open to participants now, 6 under way, none of them phase 3. Dysmenorrhea · Taiwan.
Among the 15 studies in Dysmenorrhea with a site in Taiwan, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 12 with no phase, and was the 10th registered.
432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.
Browse Dysmenorrhea studies →4 of the 15 studies in Dysmenorrhea with a site in Taiwan are open now. Recruiting first, the newest first:
China Medical University Hospital · Sites in Taiwan
Ages 20–24 · Women only
Taichung Armed Forces General Hospital · Sites in Taiwan
Ages 18–50 · Women only
China Medical University Hospital · Sites in Taiwan
Ages 18–30 · Women only · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.
This study: 20 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 82 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.
Median enrollment 60 across the 15 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
China Medical University Hospital is the lead sponsor of 480 studies on the registry; 116 are open to participants now.
China Medical University Hospital has 3 studies filed under Dysmenorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Dysmenorrhea with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07818044China Medical University HospitalIndividualized Acupoint Therapy for Dysmenorrhea: An Exploratory Research Design Based on Meridian Measurement | 2027-08-31 |
| NCT07794995China Medical University HospitalEffectiveness of an Acupressure Band for Primary Dysmenorrhea in College Students | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Dysmenorrhea with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary dysmenorrhea is a common under-diagnosed complaint, with a prevalence of about 45-95% in women of childbearing age and about 10-25% in severe cases. Menstrual pain can be classified as primary or secondary. Primary menstrual pain is a crampy pain in the lower abdomen without any pelvic pathology, which usually occurs 6 to 12 months after the first menstruation. Primary menstrual pain is usually most severe on the first day of the menstrual cycle and lasts for 8 to 72 hours. The cause is still unknown, but studies suggest that it may be related to increased prostaglandins, which cause painful contractions of the uterus. The pain is often accompanied by other menstrual discomfort symptoms, including headache, breast tenderness, drowsiness, nausea, vomiting, constipation or diarrhea, and psychological anxiety, depression or irritability. In the case of secondary menstrual pain, there are clear pelvic pathologies, such as endometriosis, uterine fibroids, and pelvic inflammatory disease.
In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400, while the placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400, all from the same batch. A bottle of nuan-gong-ye will be taken for HPLC fingerprint to examine its components. A total of 140 people will be divided randomly into two groups, of which the experimental group using nuan-gong-ye and the control group using a placebo. Four menstrual cycles of the clinical trial will be conducted after recruitment. The first menstrual cycle will be non-interventional, with subjects filling out Basic information sheet, Visual Analogue Scale (VAS), and Short Form McGill Pain Questionnaire (MPQ-SF). In the second to fourth menstrual cycles, two bottles of approximately 16 ml of nuan-gong-ye will be applied. During these three cycles, the application will begin five days before each menstrual period and end on the third day of the menstruation, with the VAS, McGill scale, and side effects questionnaire being completed. The skin should be dry before application. For each application of nuan-gong-ye or placebo, apply 10 circles clockwise from the navel to a circular area with a radius of 8 to 13 cm. The first application will be done after waking up, the second and third apply every five hours, and the fourth apply at bedtime, for a total of four applications a day. Other relief measures such as Chinese medicine, hot compresses, abdominal massage, acupuncture, and the use of other essential oils are prohibited during the research period, while painkillers are not.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Nuan-gong-ye
Other: Placebo
In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
Visual Analogue Scale (VAS)
The intensity of menstrual pain was measured by the Visual Analogue Scale (VAS). The VAS scale is a continuous horizontal line ten centimeters in length. The left end of the line, marked as 0, represents 'no pain,' while the right end, marked as 10, represents 'the most intense pain'. The VAS and McGill scales were used to assess the difference before and after each menstrual cycle.
Time frame: 4 months
Short Form McGill Pain Questionnaire (MPQ-SF)
Pain perception was measured by the Short Form McGill Pain Questionnaire (MPQ-SF). The scale consists of 15 items, with scores ranging from 0 to 3 to assess the intensity of each pain. 0 represents 'none,' 1 represents 'mild pain,' 2 represents 'moderate pain,' and 3 represents 'severe pain.' The VAS and McGill scales were used to assess the difference before and after each menstrual cycle.
Time frame: 4 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Aug 2025, 17 months after the start.
Of 179 non-industry interventional studies with no phase under Dysmenorrhea, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 17 months is above that.
Counting every sponsor, half of 189 studies reached it within 8 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China Medical University Hospital →